TBX3
TBX3 (T-box transcription factor TBX3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Colorectal cancer, Skin cancer and 3 more.
Overview
Transcriptional repressor involved in developmental processes. Binds to the palindromic T site 5'-TTCACACCTAGGTGTGAA-3' DNA sequence, or a half-site, which are present in the regulatory region of several genes. Probably plays a role in limb pattern formation.
Open Targets scores its association with cancer at 0.80 (direct and indirect evidence; datatypes affected pathway 0.30, literature 0.98, genetic association 0.73, somatic mutation 0.95, animal model 0.55). IntOGen calls it a driver in 8 cohorts (4 activating, 4 loss-of-function), covering Invasive Breast Carcinoma, Colorectal Adenocarcinoma, Diffuse Large B-Cell Lymphoma, NOS.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · TBX3 (T-box transcription factor TBX3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Colorectal cancer, Skin cancer and 3 more.
- 1 · What it is
TBX3 (T-box transcription factor TBX3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Colorectal cancer, Skin cancer and 3 more.
- 2 · What goes wrong in cancer
Transcriptional repressor involved in developmental processes. Binds to the palindromic T site 5'-TTCACACCTAGGTGTGAA-3' DNA sequence, or a half-site, which are present in the regulatory region of several genes.
- 3 · How drugs use it
No product in this corpus aims at TBX3 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:11602 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O15119 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000135111 (association with cancer (MONDO_0004992) 0.80; per-cancer scores at or above 0.5: colorectal cancer 0.62, prostate cancer 0.52, melanoma 0.59, skin cancer 0.59, breast cancer 0.75 (GraphQL API, CC0)); IntOGen TBX3 (driver in 8 cohorts (Act 4, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcriptional repressor involved in developmental processes. Binds to the palindromic T site 5'-TTCACACCTAGGTGTGAA-3' DNA sequence, or a half-site, which are present in the regulatory region of several genes. Probably plays a role in limb pattern formation. Required for mammary placode induction, and maintenance of the mammary buds during development. Involved in branching morphogenesis in both developing lungs and adult mammary glands, via negative modulation of target genes; acting redundantly with TBX2. Required, together with TBX2, to maintain cell proliferation in the embryonic lung mesenchyme; perhaps acting downstream of SHH, BMP and TGFbeta signalling. Location: Nucleus (UniProt). Locus 12q24.21 (HGNC).
- Breast cancer: Open Targets association 0.75 with breast cancer (MONDO_0007254); IntOGen driver in 5 cohorts (BRCA)
- Colorectal cancer: Open Targets association 0.62 with colorectal cancer (MONDO_0005575); IntOGen driver in 2 cohorts (COADREAD)
- Skin cancer: Open Targets association 0.59 with skin cancer (MONDO_0002898)
- Prostate cancer: Open Targets association 0.52 with prostate cancer (MONDO_0008315)
- Melanoma: Open Targets association 0.59 with melanoma (MONDO_0005105)
- Diffuse large B-cell lymphoma: IntOGen driver in 1 cohort (DLBCLNOS)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 4 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"TBX3" OR ABSTRACT:"TBX3" OR TITLE:"T-box transcription factor 3" OR ABSTRACT:"T-box transcription factor 3" OR TITLE:"T-box transcription factor TBX3" OR ABSTRACT:"T-box transcription factor TBX3" OR TITLE:"TBX3-ISO" OR ABSTRACT:"TBX3-ISO") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TBX3, not a curated reading list.